Investment case
Merck & Co., Inc.
MRK · 65 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 65 macro, policy, and market developments to Merck & Co., Inc. since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for MRK yet, so no modelled value is shown. The MRK valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run MRK on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
Co-development and commercialization of a novel oncology therapy, leveraging existing oncology infrastructure and expanding product portfolio.
· Moves peak sales estimates for oncology pipeline, probability of success for key pipeline assets, discount rate reflecting reduced clinical risk
- Main threat
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Increased competition in the NSCLC market, potentially impacting future market share for Keytruda and other oncology assets.
· Moves peak sales estimates for keytruda, market share in nsclc
- Open question
Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2
Similar large-cap pharmaceutical company facing patent expirations and relying on pipeline innovation. BMY's success could influence investor perception of the sector's ability to manage these transitions.
· Moves revenue growth rate (mid term), sector risk premium
What changed, by assumption
- 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2
- 2026-09-15Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive Rotation
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Inc. Announces Publication of Pelareorep Data in Liver Cancer | watch | 3-12m | 0.10 |
| 2026-09-29 | Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer | watch | 3-12m | 0.30 |
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Bearish | 1-3m | 0.40 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | watch | 1-5y | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation | watch | 3-12m | 0.10 |
| 2026-09-28 | HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | watch | 1-5y | 0.20 |
| 2026-09-28 | Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review | Bullish | 3-12m | 0.10 |
| 2026-09-28 | Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy Review | watch | 3-12m | 0.20 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | watch | 1-5y | 0.20 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales | Bullish | 3-12m | 0.20 |
| 2026-09-28 | HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy | watch | 3-12m | 0.20 |
| 2026-09-28 | HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate | watch | 1-5y | 0.15 |